Google Scholar | Citations: 16429| h-index: 32 | i10-index: 482
Epidemiological survey of isolated Pseudomonas aeruginosa in two laboratories in the city of Governador Valadares, Minas Gerais, Brazil in the year 2018
PDF (Portuguese (Brazil))

Keywords

Pseudomonas aeruginosa
Resistance
Anti-Bacterial Agentes
Prevalence

How to Cite

Epidemiological survey of isolated Pseudomonas aeruginosa in two laboratories in the city of Governador Valadares, Minas Gerais, Brazil in the year 2018. (2019). Electronic Journal Collection Health, 11(18), e1658. https://doi.org/10.25248/reas.e1658.2019

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

Abstract

Objective: To analyze the prevalence of Pseudomonas aeruginosa strains in two laboratories in the city of Governador Valadares, Minas Gerais in 2018. Methods: Descriptive study, retrospective, with quantitative approach. Results: They had 148 positive samples for P. aeruginosa. The predominant age group for Laboratory 1 was 81–90 years (28%), and for Laboratory 2 the age group with highest significance was 41–50 years (29%). As for sites, three stand out with the highest prevalence of positivity: blood (2.2%) and (71.5%) in Laboratory 1 and 2, respectively; secretions in Laboratory 1(25.4%) and Laboratory 2(7.1%). For urine, in Laboratory 1 (42.5%) and in Laboratory 2(21.4%). As for the resistance factor, it was found that P. aeruginosa showed resistance to Amicacine antimicrobials, only in Laboratory 1(17.4%); Cefeprime, Laboratory 1(34.1%) and Laboratory 2(14.2%); Ciprofloxacino, Laboratory 1(38.1%) and Laboratory 2 (21.4%); Gentamicine, Laboratory 1(35.6%) and Laboratory 2(21.4%); Meropenem, only Laboratory 1(27.7%) and, Piperacillin / Tazobactam, only Laboratories 1(12.5%). Conclusion: Further comparative studies are suggested using laboratory samples with longer period to verify the prevalence of these samples and the evolutionary flow of resistance rates.

PDF (Portuguese (Brazil))